Application

Quality Control TestingWestern Blotting Analysis (WB): Analysis: A 1:1,000 dilution of this antibody detected human IFN-g protein.Tested applications Western Blotting Analysis (WB): A 1:1000 Dilution of this antibody detected IFN- g in NK-92 cell lysate. Flow Cytometry Analysis: 1 μg from a representative lot detected IFN- in one million HuPBMC.Immunocytochemistry Analysis: A 1:1,000 dilution from a representative lot detected IFN- in NK-92 cells treated with Brefeldin A (BFA; 300 ng/ml, 4 hours) or stimmed and treated with BFA.Affinity Binding Assay:: A representative lot of this antibody bound IFN-g with a KD of 2.3 x 10-8 in an affinity binding assay.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Anti-IFN-g, clone 5K15 ZooMAb, Cat. No. ZRB1620, is a recombinant Rabbit monoclonal antibody that specifically targets IFN-g and is tested for use in Affinity Binding Assay, Flow Cytometry, Immunocytochemistry, and Western Blotting.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

Full-length mature recombinant human Interferon- g (without signal and propeptide).

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 5K15 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects human Interferon- g.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

Interferon- g (UniProt: P01579; also known as IFN-gamma, IFN- g, Immune interferon) is encoded by the IFNG gene (Gene ID: 3458) in human. IFN-g is a pleiotropic molecule with antiproliferative, pro-apoptotic, and antitumor properties. It is a type II homodimeric interferon that is synthesized with a signal peptide (aa 1-23) and a propeptide (aa 162-166) that are subsequently cleaved off to produce the mature form. It is secreted predominantly by activated lymphocytes such as CD4 T helper type 1, CD8 cytotoxic T cells, g T cells, and natural killer cells, and antigen-presenting cells. Its expression is induced by mitogens and cytokines. IFN- g signaling coordinates several biological responses involved in host defense and immune surveillance, establishment of adaptive immunity, and the regulation of inflammation. Its diverse biological activities are initiated by IFN- g -mediated aggregation of at least two different cell surface receptors: IFN g R1 and IFN g R2. IFN-g is reported to activate macrophages toward a pro-inflammatory profile increasing their phagocytic ability and enhancing their microbial killing activity. It is also shown to upregulate cell surface MHC class II on antigen presenting cells, thus promoting peptide-specific activation of CD4 T cells. Mutations in IFNG gene are known to cause aplastic anemia that is characterized by failure of bone marrow to produce adequate number of peripheral blood elements leading to peripheral pancytopenia and hypoplasia. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Castro, F., et al. (2018). Front. Immunol. 9; 847).